BIM-46187 is a novel, potent and heterotrimeric pan G protein complex inhibitor. It specifically silences Gαq proteins by 'freezing' Gαq in its empty pocket conformation, a conformational intermediate along the Gα activation pathway.
Physicochemical Properties
| Molecular Formula | C44H58N8O2S2 |
| Molecular Weight | 795.11372 |
| Exact Mass | 794.412 |
| CAS # | 892546-37-1 |
| PubChem CID | 11593027 |
| Appearance | White to light yellow solid powder |
| LogP | 9.133 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 13 |
| Heavy Atom Count | 56 |
| Complexity | 1160 |
| Defined Atom Stereocenter Count | 4 |
| SMILES | C(C1CCCCC1)[C@@H]1N(C(=O)[C@@H](N)CSSC[C@H](N)C(N2CCN3C=C(C4C=CC=CC=4)N=C3[C@@H]2CC2CCCCC2)=O)CCN2C=C(C3C=CC=CC=3)N=C12 |
| InChi Key | GGDNOAWICIHSAW-KEAHXZLPSA-N |
| InChi Code | InChI=1S/C44H58N8O2S2/c45-35(43(53)51-23-21-49-27-37(33-17-9-3-10-18-33)47-41(49)39(51)25-31-13-5-1-6-14-31)29-55-56-30-36(46)44(54)52-24-22-50-28-38(34-19-11-4-12-20-34)48-42(50)40(52)26-32-15-7-2-8-16-32/h3-4,9-12,17-20,27-28,31-32,35-36,39-40H,1-2,5-8,13-16,21-26,29-30,45-46H2/t35-,36-,39-,40-/m0/s1 |
| Chemical Name | (2R,2'R)-3,3'-disulfanediylbis(2-amino-1-((S)-8-(cyclohexylmethyl)-2-phenyl-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)propan-1-one) |
| Synonyms | PH-064 PH 064 PH064 BIM-46187 BIM 46187 BIM46187 |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| References | The novel inhibitor of the heterotrimeric G-protein complex, BIM-46187, elicits anti-hyperalgesic properties and synergizes with morphine. Eur J Pharmacol. 2008 Oct 10;594(1-3):70-6.; Crosstalk between angiotensin and the nonamyloidogenic pathway of Alzheimer's amyloid precursor protein. FEBS J. 2017 Mar;284(5):742-753. doi: 10.1111/febs.14015. Epub 2017 Feb 10. PubMed PMID: 28102934. |
Solubility Data
| Solubility (In Vitro) | DMSO : ~100 mg/mL (~125.77 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.14 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.14 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (3.14 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2577 mL | 6.2884 mL | 12.5769 mL | |
| 5 mM | 0.2515 mL | 1.2577 mL | 2.5154 mL | |
| 10 mM | 0.1258 mL | 0.6288 mL | 1.2577 mL |